

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 207A  
Serial No. : to be assigned  
Applicant: : Wang et al.  
Date Filed : Concurrently herewith  
For : METHODS OF USING IL-1  
ANTAGONISTS TO TREAT  
NEOINTIMAL HYPERPLASIA

Examiner : Not Yet Known  
Group Art Unit : Not Yet Known

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/Subclass</u>	<u>Filing Date</u>
_____	_____	_____	_____	_____	_____

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/Subclass</u>	<u>Translation Yes</u> <u>No</u>
_____	_____	_____	_____	_____	_____

REG 207A  
USSN to be assigned  
PTO 1449 Form  
Wang et al.  
Page 2

#### OTHER DOCUMENTS

Examiner  
Initials

XZ

Rectenwald et al. (2000) Circulation 102: 1697-1702

EXAMINER  
CONSIDERED

DATE

Kenya R.

10/11/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By: Valeta Gregg  
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400



FORM PTO-1449

Att. Docket No. 207A

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant : Wang et al.  
Serial No. : 10/840,138  
Date Filed : May 6, 2004  
For : METHODS OF USING IL-1  
ANTAGONISTS TO TREAT  
NEOINTIMAL HYPERPLASIA  
Examiner : To be Assigned  
Group Art Unit : 1632

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/ Subclass</u>	<u>Filing Date</u>
XZ	5,135,917	Aug. 4, 1992	Ronald M. Burch		

## FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes</u>	<u>No</u>
XZ	WO 00/71753 A2	30 Nov 2000	PCT			
YZ	WO 93/24134	9 Dec 1993	PCT			
XZ	WO 00/18932	06 Apr. 2000	PCT			

207A  
U.S. Serial No. 10/840,138  
PTO 1449 Form  
Wang et al.  
Page 2

X2      WO 02/16436 A2    28 Feb. 2002    PCT  
X2      WO 04/022718 A2    18 Mar. 2004    PCT

#### OTHER DOCUMENTS

Examiner  
Initials

X2      US Patent Application Publication No. US 2001/0053764 A1, Publication Date: December 20, 2001; "Interleukin-1 Inhibitors in the Treatment of Diseases".  
X2      US Patent Application Publication No. US 2003/0026806 A1, Publication Date: February 6, 2003; "Antibodies and Other Selective IL-1 Binding Agents that Allow Binding to IL-1 Receptor But Not Activation Thereof".

EXAMINER  
CONSIDERED

DATE

Deeghdr.      10/11/06

EXAMINER:      Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,  
By: Valeta Gregg  
Valeta Gregg  
Reg. No. 35,127  
Attorneys for Applicant  
Patent Agent for Applicant  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400